Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Integrated fatty acid profiling unveils a linkage between BMI and efficacy of anti-tumor immunotherapy

Award Number: K99CA297133
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 06/04/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Integrated fatty acid profiling unveils a linkage between BMI and efficacy of anti-tumor immunotherapy - PROJECT SUMMARY/ABSTRACT Immunotherapy has proven effective against cancer, but it encounters challenges in overcoming resistance and maximizing efficacy. Identifying substances to enhance immunotherapies is crucial. Paradoxically, emerging evidence suggests a link between mild obesity and improved outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs). Considering that circulating free fatty acids (FFAs) can impact various immune cells and serum FFA levels are elevated in obesity, we hypothesize that certain circulating FFAs may serve as immunomodulators, enhancing anti-tumor immunity for improved cancer treatment. We systematically compare the levels of FFAs in the serum of 43 melanoma patients who responded or did not respond to ICI therapy. Additionally, we curated a library of 62 commercially available FFAs present in the human body to identify those enhancing immune cell functions. Applying these approaches, we revealed the crucial role of essential fatty acids (EFAs) in regulating CD8+ T cells, thereby boosting anti-tumor immunity. We discovered that six FFAs within the EFA pathway significantly influenced CD8+ T cells. Arachidonic acid (AA), Eicosapentaenoic acid (EPA), and Docosahexaenoic acid (DHA) enhanced immune responses, while Linoleic acid (LA), γ-Linolenic acid (GLA), and α-Linolenic acid (ALA) had inhibitory effects. Notably, the EFAs promoting immunity are positioned downstream in the EFA pathway (DEFA), while those inhibiting immunity are situated upstream in the EFA pathway (UEFA). We observed that the oral administration of DEFAs enhances anti-tumor immunity, whereas UEFAs promote tumor growth in vivo. Our mechanistic studies reveal that the EFAs effects on CD8+ T cells are through GPCR. DEFAs have a different interaction pattern with GPR120 compared to UEFAs. I thus hypothesize that the differential structural interactions of DEFAs and UEFAs with GPR120 contribute to reprogramming CD8+ T cells and anti-tumor immunity. Three specific aims are: (1) To investigate whether DEFAs and UEFAs distinctly modulate CD8+ T cell function and impact anti-tumor immunity in vivo, both individually and in combination with ICI. Additionally, we aim to measure serum EFA levels in lymphoma patients treated with CAR T-cell therapy. (2) To validate whether GPR120 is the target of EFAs in CD8+ T cell regulation, and to delve into the structural-based mechanisms underlying the distinct regulatory effects of DEFAs and UEFAs on CD8+ T cells through GPR120. Moreover, we will perform structure-activity research (SAR) studies and design new derivatives of DEFAs with improved potency and efficacy to enhance CD8+ T cell function and anti-tumor immunity. (3) To investigate the impact of FFAs on diverse immune cells, encompassing CD4+ T cells, dendritic cells (DCs), natural killer (NK) cells, and innate lymphoid (ILC) cells, as well as their implications for anti-tumor immunity.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $129,285 )
2026	2026	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Research Manpower	000	1	6/8/2026	NEW	$129,285
														Subtotal = $129,285

Grand Total All Awards = $129,285

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Integrated fatty acid profiling unveils a linkage between BMI and efficacy of anti-tumor immunotherapy

Award Number: K99CA297133

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 06/04/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer